Related Experiment Video
Updated: Nov 15, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
The Discovery of a Novel Antimetastatic Bcl3 Inhibitor
Jitka Soukupová1,2, Cinzia Bordoni1, Daniel J Turnham2
1School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom.
Abstract:
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options are limited and often associated with poor long-term survival and systemic toxicities. Bcl3, a facilitator protein of the NF-κB family, is associated with poor prognosis in a range of tumor types. Bcl3 has been directly implicated in the metastasis of tumor cells, yet is well tolerated when constitutively deleted in murine models, making it a promising therapeutic target. Here, we describe the identification and characterization of the first small-molecule Bcl3 inhibitor, by using a virtual drug design and screening approach against a computational model of the Bcl3-NF-kB1(p50) protein-protein interaction. From selected virtual screening hits, one compound (JS6) showed potent intracellular Bcl3-inhibitory activity. JS6 treatment led to reductions in Bcl3-NF-kB1 binding, tumor colony formation, and cancer cell migration in vitro; and tumor stasis and antimetastatic activity in vivo, while being devoid of overt systemic toxicity. These results represent a successful application of in silico screening in the identification of protein-protein inhibitors for novel intracellular targets, and confirm Bcl3 as a potential antimetastatic target.
Insights
Researchers developed a novel small-molecule inhibitor (JS6) targeting the Bcl3 protein, a key factor in cancer metastasis. This drug shows promise in reducing tumor growth and spread with minimal toxicity, offering a new avenue for antimetastatic therapies.
Area of Science:
- Oncology
- Drug Discovery
- Molecular Biology
Background:
- Metastasis accounts for approximately 90% of cancer deaths, highlighting the urgent need for effective antimetastatic drugs.
- Current treatments for metastasis are limited, often causing significant systemic toxicities and poor long-term survival rates.
- Bcl3, a nuclear factor kappa B (NF-κB) family protein, is linked to poor prognosis and directly implicated in tumor cell metastasis.
Purpose of the Study:
- To identify and characterize the first small-molecule inhibitor targeting the Bcl3 protein.
- To evaluate the therapeutic potential of Bcl3 inhibition as an antimetastatic strategy.
- To demonstrate the efficacy of in silico screening for discovering inhibitors of protein-protein interactions.
Main Methods:
- Utilized virtual drug design and screening against a computational model of the Bcl3-NF-kB1(p50) protein-protein interaction.
- Identified and characterized a lead compound, JS6, for its Bcl3-inhibitory activity.
- Assessed the effects of JS6 on Bcl3-NF-kB1 binding, tumor colony formation, cancer cell migration in vitro, and tumor stasis and antimetastasis in vivo.
Main Results:
- JS6 demonstrated potent intracellular Bcl3 inhibition and reduced Bcl3-NF-kB1 binding.
- JS6 treatment significantly inhibited tumor colony formation and cancer cell migration in vitro.
- In vivo studies showed JS6 induced tumor stasis and exhibited antimetastatic activity without overt systemic toxicity.
Conclusions:
- Bcl3 is a viable and promising therapeutic target for developing novel antimetastatic drugs.
- JS6 represents the first small-molecule inhibitor of Bcl3, validating its potential for cancer therapy.
- In silico screening is an effective approach for identifying inhibitors of protein-protein interactions for intracellular targets.
